Manager TitleAgeSince
Investor Relations Contact - -
Corporate Officer/Principal - 10/04/2023
Date Insider Type Main position Quantity % Market Cap.
10/04/23 Free

Executive/Senior Manager

4,00,000 0.6684%
01/02/23 Free

Chief Operating Officer

4,00,000 0.6686%
01/02/23 Free

Chief Financial Officer

4,00,000 0.6686%
Change 5-day change 1-year change 3-year change Capi.($)
-13.39%-23.18% - - 29.5L
+0.21%-1.34%+53.17%+60.65% 5.38TCr
+5.37%+0.75%+50.39%+83.03% 5.21TCr
-1.20%-0.62%+5.53%+409.46% 2.35TCr
+0.74%+2.20%-15.48%-14.55% 2.31TCr
+3.46%+0.79%+34.01%-4.47% 1.94TCr
-1.18%-1.15%+30.12%-32.02% 1.76TCr
-1.67%-8.56%+163.95%+284.69% 1.52TCr
+3.62%-2.42%+29.70%+663.64% 1.48TCr
-0.70%+0.36%+27.07%+183.04% 1.41TCr
Average -0.20%-0.34%+42.05%+181.50% 2.6TCr
Weighted average by Cap. +1.70%-0.73%+41.79%+141.13%
Logo Aravive, Inc.
Aravive, Inc. is a clinical-stage oncology company. The Company is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The Company's lead product candidate, Batiraxcept, is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the United States Food and Drug Administration (FDA) for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase III trial in platinum-resistant ovarian cancer (NCT04729608), a Phase Ib/II trial in clear cell renal cell carcinoma (NCT04300140), and a Phase Ib/II trial in pancreatic adenocarcinoma (NCT04983407).
Employees
23
  1. Stock Market
  2. Stocks
  3. ARAV Stock